Business
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"\n Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments\n Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and concludes that VMAT2 inhibitors are not clinically interchangeable\n Publication provides a comprehensive resource containing clinical study results, safety profiles and use considerations to support treatment decisions\n \n \n SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade of clinical research on two FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors – INGREZZA® (valbenazine) capsules and deutetrabenazine – for the treatment of tardive dyskinesia. Among key insights, the review highlights the distinct profiles of VMAT2 inhibitors approved for tardive dyskinesia and presents unique attributes of INGREZZA: selectivity to VMAT2, a therapeutic response at the lowest available 40 mg dose and data across a wide range of patient populations. VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia: A Narrative Review has been published in CNS Spectrums.\n \n \n \n \n \n \n \n \"This inclusive resource will help inform healthcare providers to further understand the differences between the two available VMAT2 inhibitors for tardive dyskinesia, with the goal of supporting optimal treatment decisions for each patient,\" said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. \"The review findings highlight how these distinctions can carry meaningful clinical implications for drug selection, emphasizing that appropriate treatment depends on understanding each medication's unique mechanism, safety profile and dosing requirements. Notably, this includes the distinctive profile of INGREZZA with no-titration dosing and comprehensive clinical evidence.\"\n Authored by experts in psychiatry and neurology, the review highlights key differences between the two drugs. It reinforces that although both act on the VMAT2 receptor, they are not inte...